Shenzhen Weiguang Biological Products Co., Ltd. (SHE:002880)
China
· Delayed Price · Currency is CNY 25.74
+0.06 (0.23%)
Apr 29, 2026, 3:04 PM CST
SHE:002880 Revenue
Shenzhen Weiguang Biological Products had revenue of 221.87M CNY in the quarter ending March 31, 2026, a decrease of -1.39%. This brings the company's revenue in the last twelve months to 1.26B, up 5.13% year-over-year. In the year 2025, Shenzhen Weiguang Biological Products had annual revenue of 1.27B with 5.28% growth.
Revenue (ttm)
1.26B
Revenue Growth
+5.13%
P/S Ratio
4.62
Revenue / Employee
1.47M
Employees
859
Market Cap
5.84B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.27B | 63.47M | 5.28% |
| Dec 31, 2024 | 1.20B | 154.69M | 14.75% |
| Dec 31, 2023 | 1.05B | 380.57M | 56.98% |
| Jan 1, 2023 | 667.93M | -239.50M | -26.39% |
| Jan 1, 2022 | 907.43M | 2.87M | 0.32% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PharmaResources (Shanghai) | 667.47M |
| Lifecome Biochemistry | 502.95M |
| Novogene | 2.26B |
| Shouyao Holdings (Beijing) Co., LTD. | 34.67M |
| Kexing Biopharm | 1.53B |
| Innovita Biological Technology | 422.03M |
| Beijing Konruns Pharmaceutical | 917.99M |
| Beijing Scitop Bio-tech | 373.31M |